ExploreWatchlistsPricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Cash and cash equivalents

ReproCELL Incorporated (4978)

Market cap
¥16.2B
P/E ratio
-28.2x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 20252,823-3.94%
Mar 31, 20242,939+53.51%
Mar 31, 20231,915-27.53%
Mar 31, 20222,642+1.56%
Mar 31, 20212,601-43.27%
Mar 31, 20204,586+11.50%
Mar 31, 20194,113+15.09%
Mar 31, 20183,573+4.69%
Mar 31, 20173,413+0.12%
Mar 31, 20163,409+16.83%
Mar 31, 20152,918

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat